HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.

AuthorsTomoo Ikari, Jun Sakakibara-Konishi, Gaku Yamamoto, Hidenori Kitai, Hidenori Mizugaki, Hajime Asahina, Eiki Kikuchi, Naofumi Shinagawa
JournalClinical lung cancer (Clin Lung Cancer) Vol. 20 Issue 4 Pg. e531-e533 (07 2019) ISSN: 1938-0690 [Electronic] United States
PMID31164318 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors
Topics
  • Acrylamides (therapeutic use)
  • Aged
  • Aniline Compounds (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, mortality)
  • Drug Resistance, Neoplasm (genetics)
  • ErbB Receptors (genetics)
  • Humans
  • Lung Neoplasms (drug therapy, genetics, mortality)
  • Male
  • Mutation (genetics)
  • Neoplasm Metastasis
  • Protein Kinase Inhibitors (therapeutic use)
  • Remission Induction
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: